In apolipoprotein E (ApoE)−/− atherosclerosis models, 8-week oral F1 treatment at 50 mg/kg/day induced remarkable reduction in atherosclerotic lesion area and decreased lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and TLR4 expression [82]. Here, OLR1 is linked to atherosclerosis.